This morning, the entire world press wrote about the fact that the Chinese CanSinoBIO recombinant new coronavirus vaccine was approved for emergency use by the Hungarian National Institute of Pharmaceutical and Nutritional Sciences (OGYÉI) in the III. based on the interim results of a phase II clinical trial.
The vaccine, called Ad5-nCoV, is effective with a single dose and was approved for emergency use in Mexico and Pakistan in February. Mexico signed a framework contract for 35 million doses, of which 5 million have been received so far. Its documentation is also being examined in Russia and Chile, but Hungary is the first in Europe to have approved it for emergency use.
The vaccine uses an adenovirus to deliver the genetic material of the coronavirus into the body and trigger an immune response. Vaccines from AstraZeneca and Johnson & Johnson work in a similar way. It is the first Chinese-developed vaccine that requires only one dose.
In severe cases, the vaccine was reported to be 95.47 percent effective after a single vaccination at 14 days and 90.98 percent effective at 28 days after vaccination. The vaccine can be given to anyone from the age of 18. Serious side effects were not reported anywhere, and the incidence of mild side effects is even lower in the elderly population.
The vaccine was created by CanSinoBIO, led by Chen Wei, an expert on military infectious diseases at the Institute of Biotechnology of the Military Academy of Military Sciences.
It is not yet known when and how many doses CanSinoBIO will deliver to Hungary.
